Management Presentation: Biosimilar Pipeline and Margin Improvement Strategy
Attractive market fundamentals | Leadership and scale | Multiple growth drivers Margin improvement | Attractive financial outlook | Compelling sustainability story
E Expanding breadth and depth of pipeline
2x
expected overall launch contribution
to net sales in the next five years¹
>400
Generics
in pipeline
25
Biosimilars
in pipeline
~3x
number of Biosimilars in
development over the last five years
Increasing contribution
from complex products
Focused on
high-value opportunities
-50%
of launch contribution to net sales
expected to be derived from
Biosimilars in the next five years
>USD 145bn
of originator sales covered²
>USD 206bn
of originator sales covered³
Note: The third-party trademarks above are property of their respective owners; 1. Compared to prior five years, for both Generics and Biosimilars; 2. LoE value covered based on Company analysis using Sandoz IP and IP database;
3. Originator sale covered based on Company analysis using Evaluate Pharma; at full year prior to expected market formation year.
17
Management Presentation
SANDOZView entire presentation